Centerpulse strength helps Zimmer beat Q4 guidance
This article was originally published in Clinica
Executive Summary
Announcing its first set of revenues incorporating those of Swiss orthopaedics and reconstructive surgery group Centerpulse, Zimmer yesterday said that its sales for the fourth quarter of 2003 are likely to come in at $700m, beating Wall Street's First Call projections ($666m) by 10%. EPS (before acquisition costs, write-offs and inventory step-up) is expected to outperform consensus guidance of $0.44 by 11% at least.